OUR PRODUCT OFFERs AN INNOVATIVE SOLUTION TO OXYGEN DEPRIVATION

A HEMOGLOBIN-BASED OXYGEN CARRIER

Oxygen therapeutics are agents designed to deliver oxygen normally carried by red blood cells (RBCs)

ABOUT OUR PRODUCT

For more than 100 years researchers have pursued the “Holy Grail” of trauma medicine: a solution that would retain all the functions of blood without the transfusion problems associated with blood. Although no single product can yet imitate all the properties of blood, substantial progress has been made, especially in the development of HBOCs. Although some products have come close, no HBOC has yet been approved for clinical use in the U.S. or Europe.

Hemoglobin is the main component of RBCs, comprising about 33% of the cell mass. Hemoglobin-based Oxygen Carriers (HBOCs) work much like ordinary RBCs. The molecules of the HBOC float in the blood plasma, picking up oxygen from the lungs and dropping it off in the capillaries.

The molecules are much smaller than RBCs, so they can fit into spaces that RBCs cannot, such as into extremely swollen tissue or abnormal blood vessels around cancerous tumors. Most HBOCs stay in a person’s system for about a day – far less than the 100 days or so that ordinary RBCs circulate

Product safety and reliability are our primary goals. We will achieve these goals by highly purifying our product and utilizing single-use components. Single-use technology provides cleaner products and better control of the process, while being cost-effective and scale-able to meet demand.

OUR PRODUCT IS HIGHLY PURIFIED TO OPTIMIZE SAFETY AND RELIABILITY

Single-use technology provides cleaner products and better control of the process, while being cost-effective and scale-able.

THE HISTORY OF 8BIOMED

BUILDING ON A VISION

During the 1990s there was an immense amount of interest in hemoglobin-based oxygen carriers (HBOCs) as a substitute for blood transfusions. HBOCs eliminate the need for matching blood types, do not require refrigeration, and support a longer shelf life than banked blood.

Several technologies were tried, but none gained FDA approval for use in humans. One product was approved for human use in South Africa and Russia – a bovine blood-derived, polymerized hemoglobin. Manufacture of this product stopped in the early 2000s for a variety of reasons.

Medical Technology Associates II (“MTA2”) was established in 2015 to re-commercialize the bovine blood-derived HBOC technology with new production processes, product configurations and applications. Now operating in Malvern, Pennsylvania in a completely re-fitted manufacturing space, MTA2, doing business as 8BioMed, is developing a modified process to enhance safety while still providing all the benefits of an oxygen therapeutic.

WHAT DOES THE FUTURE
HOLD FOR 8BIOMED?

WHAT DOES THE FUTURE HOLD FOR 8BIOMED?

OUR PATH FORWARD

The future of 8BioMed holds many possibilities. We are currently investigating our product for use in trauma, both in humans and animals, and as a means of keeping transplant organs viable longer. But that is not all our product has the potential to do.

Oxygen therapy is often prescribed for people who cannot access enough oxygen on their own due to conditions that prevent the lungs from absorbing it. We will investigate our product as a therapeutic option for these conditions, which include COPD, pneumonia, asthma, bronchopulmonary dysplasia, underdeveloped lungs in newborns, heart failure, cystic fibrosis, and sleep apnea.

Other indications for which 8BioMed may investigate are wound healing, including diabetic wounds, pressure ulcers, and skin grafts. Our product may be candidate to treat brain and nerve problems such as MS, Parkinson’s, neuropathy, fibromyalgia, epilepsy and dementia.

8BioMed product may also be investigated as a treatment for certain cancers. Oxygen therapy via hyperbaric chambers has been used for years as a cancer treatment. Direct injections of 8BioMed product may be more efficient and a more targeted procedure than sessions in a hyperbaric chamber.

JOIN OUR TEAM

SEE OUR CURRENT OPENINGS